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Abstract
Common sequence variations in the VRK2 gene contribute to genetic risk for various psychiatric diseases including schizo-
phrenia and major depressive disorder. Despite the clear importance of studying the regulation and function of VRK2 for 
understanding the causes of these diseases, the organisation and expression of the gene remain poorly characterised. Using 
reverse-transcriptase-PCR, we have amplifed exons of Vrk2 mRNA from regions of mouse brain, and from different cell 
classes comprising neurones, astrocytes and microglial cells. We find that Vrk2 mRNA is expressed in all cell types, and 
that the splicing of the mouse Vrk2 gene is much more complex than previously appreciated. In addition to the predicted 
alternative splicing (absence/presence) of the penultimate 3 prime exon, we also detected a variety of 5 prime structures, 
including two novel exons spanning the first characterised exon (exon 1), which we term exons 1a and 1b. While expressed 
in neurones and astrocytes, exon 1b was not expressed in microglial cells. Expression of transcripts containing exon 1a in 
microglia was increased by immune stimulation. An additional truncated transcript lacking 7 central exons was also identi-
fied. As with the human gene, the results confirm complex patterns of alternative splicing which are likely to be relevant for 
understanding the physiological and pathological function of the gene in the CNS.
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Introduction
The Type 2 Vaccinia Related Kinase (VRK2) gene codes for 
a serine threonine kinase belonging to the casein kinase 1 
group, and is situated in the 2p16.1 chromosomal region. 
VRK2 was initially recognised in highly proliferative cells 
(e.g. thymus and foetal liver cells) and early theories empha-
sised a role in cell division and cell cycle regulation [1]. 
VRK2’s importance is however not limited to proliferating 
peripheral cells, and it was subsequently found to be also 
expressed in brain [2]. In fact, sequence variants in the VRK2 
gene are robustly associated with schizophrenia [3–5], and 
also with depression [6], bipolar disorder [7], and epilepsy 
[8, 9]. Tesli et al. (2016) [10] demonstrated reduced blood 
levels of VRK2 mRNA in a large sample of individuals 
with schizophrenia relative to controls (p < 10− 12), thereby 
strongly supporting a genetic contribution of VRK2 to the 
causes of schizophrenia. This result has since been repli-
cated in an independent large sample [11]. It has recently 
been reported that in the brain, Vrk2 expression is restricted 
to microglia [12] If this were verified, this would be of some 
significance for understanding the causes of schizophrenia, 
as it would unequivocally implicate microglial dysfunction 
in disease aetiology.
Blanco et  al. [13] identified two isoforms of human 
VRK2 that have a kinase domain in common, but differ-
ing subcellular locations due to distinct C-termini. Thus, 
VRK2A (where the penultimate 3 prime exon - exon 13 - is 
absent)(Fig. 1) encodes a 508 amino acid protein which has 
a transmembrane domain and is localised in the endoplasmic 
reticulum and mitochondrial membrane. In contrast, VRK2B 
(where exon 13 is present) encodes a shorter 397 amino acid 
protein, due to the presence of an earlier stop codon, lacks 
this domain, and is present in the cytoplasm and the nucleus. 
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While VRK2A is significantly expressed in all human cell 
lines, expression of VRK2B is more limited and occurs only 
in certain cell lines. Blanco et al. [14] further noted that the 
stress responses to cytokines such as interleukin 1β (IL-1β) 
and to hypoxia are regulated by the more abundant VRK2A. 
VRK2 forms a complex with JIP1 [15], which functions as a 
scaffold protein for the c-Jun N-terminal kinase (JNK) path-
way by building mitogen-activated protein kinase (MAPK) 
complexes. This signal transmission route is reportedly 
blocked by VRK2A, thus limiting the phosphorylation of 
JNK and AP1-dependent transcription, and hence transmis-
sion of this stress signal. By contrast, the VRK2B isoform 
in the nucleus can reduce the transcriptional response to the 
inflammatory cytokine interleukin-1β [15].
Examination of Genbank and the European Nucleo-
tide Archive databases suggests the existence of further 
Fig. 1  Schematic diagram of intron/exon structure for human (upper) 
and mouse(lower) VRK2 genes, from 5’ end (left) to 3’end (right). 
Isoform designations provided are according to RefSeq annotations. 
Relative lengths of exons/introns are for illustrative purposes, and are 
only very roughly proportional to actual distances. Approximate loca-
tions of PCR primers used in this study are also shown
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alternative splicing in human (Fig. 1), mainly focussed 
around the 5’ end of the mRNA. The mouse Vrk2 gene is 
recognised as having 13 rather than 14 exons [16], and one 
of the annotated REFSEQ transcripts lacks the penultimate 
exon (exon 12)(Fig. 1). However, some of the transcripts 
predicted by automated genome sequence scanning sug-
gest that there may be further transcript diversity in the 
mouse, as in the human. Since future studies on Vrk2 gene 
function will be needed to explore the genetic basis of 
psychiatric disease, an understanding of gene structure is 
a necessary first step. We therefore undertook an investiga-
tion of the extent of alternative splicing in mouse brain, 
and in different cell types within the brain, to clarify the 
structure of expressed Vrk2 mRNAs, and the effect of cell 
type and environment on Vrk2 gene expression.
Materials and methods
Culture of primary cells ‑ preparation of neurons 
and astrocytes
Primary cerebrocortical neuronal cultures were pre-
pared using brain tissue from wild-type C57BL/6J mouse 
embryos (E17) as previously described [17–19], and main-
tained for 12–14 dayd in vitro (DIV). For primary astro-
cyte cultures [20], the medium was changed every 2 to 3 
days, and then, to deplete as many microglia as possible, 
the flask was shaken at 100 rpm for 30 min on an orbital 
shaker. After confluency was reached, trypsin-EDTA and 
HEPES (final concentration 50 mM) were added until the 
astrocyte containing cell layer slowly detached from the 
culture flask, while the microglia stayed attached.
The quality and purity of neuronal and astrocyte cul-
tures has been repeatedly checked – cultures are in good 
health and are around 90% specific for the defined cell type 
[17–19], as is standard for these techniques.
Culture of cells ‑ preparation of microglia cells
SIM-A9 cells (ATCC, #CRL-3265), which are a spon-
taneously immortalized mouse microglial cell line [21, 
22], were were maintained in DMEM/F12 medium serum 
(Invitogen, Paisley, UK) supplemented with 5% horse 
serum (Invitogen, Paisley, UK) and 1% penicillin-strepto-
mycin serum (Invitogen, Paisley, UK), at 37 °C. Cells were 
used at passage 12–15. The culture medium was replaced 
with DMEM/F12 medium without horse serum at 50 to 
60% confluence overnight prior to the indicated treatment 
( 100 ng/mL LPS or vehicle control) for 24 h.
RNA isolation
RNA isolation from cells
Total RNA was isolated from cells by removing the 
medium from the wells, and the cells being washed with 
phosphate-buffered saline (D-PBS, Invitrogen). The cells 
were then detached from the well surface using 0.05% 
trypsin and inactivated by the addition of 0.5 ml DMEM. 
The detached cells were transferred to a tube and pelleted 
by centrifugation at 10,000 rpm for 5 min at room tem-
perature. Each cell pellet was washed with D-PBS and 
centrifuged again at 10,000 rpm for 5 min at room tem-
perature. Following this, an RNeasy mini kit (Qiagen, 
#74104) was used to isolate total RNA from the cells as 
described above.
RNA isolation from mouse brain tissues
Total RNA was isolated from mouse C57BL/6J brain tis-
sue using the RNeasy mini kit (Qiagen, #74104) accord-
ing to the manufacturer’s protocols, and as previously 
described [23, 24]. Brain tissues were removed from the 
RNAlater and placed in ribolyser tubes on ice (Lysing 
matrix D, BIO 101 Systems, cat. No. 6913 − 100), being 
subject to mechanical disruption for 20 s at 6.5 g using 
Hybaid Ribolyser. Following this, an equal volume of 70% 
ethanol was added to each sample, and the resulting mixes 
were transferred to an RNeasy column and centrifuged at 
10,000 rpm for 15 s at room temperature. The total RNA in 
the columns then underwent multiple wash steps, includ-
ing a DNA removal step with an incubation period of 15 
min at room temperature. Total RNA was eluted from 
the columns and the concentration of the isolated RNA 
checked using a NanoDrop™ 1000 (Thermo Scientific).
Reverse transcription and PCR
cDNA synthesis
The reverse transcriptase step was performed using a 
high-capacity RNA to cDNA kit (Thermo fisher scien-
tific, #4387406) according to manufacturer’s instructions. 
For each reaction, 500 ng to 2 µg of total RNA was used 
per 20µL reaction. First strand cDNA was generated by 
incubating the tube contents at 37 °C for 60 min, then 
terminating the reaction at 95°C for 5 min. The quantity 
of cDNA produced was checked using NanoDrop™ 1000 
(Thermo Scientific). Following this, samples were diluted 
at a 1:5 ratio and stored at −20 °C for further processing.
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Polymerase chain reaction
Several 10 µl PCR reactions were set up using 0.3 µl of suit-
able forward and reverse primers, plus 2 µl of cDNA, 0.5 µl 
of DMSO and 5 µl of Platinum™ Taq Green Hot Start (Inv-
itrogen, # 11966034). No template controls were included. 
The standard PCR reaction conditions were 3 min at 95 °C 
and then 40 cycles of 30 s at 95 °C, 30 s at 60 °C, and 1 
min at 72 °C. The latter step was modified to 90 s when 
the expected product was greater than 1,000 bp. The final 
elongation step was at 72 °C for 7 min. Primer sequences are 
provided in Supplementary Table 1.
Gel electrophoresis and visualisation of amplicons
PCR products were separated out by gel electrophoresis 
in a 2% agarose gel made of UltraPure™ Agarose (Invit-
rogen, #16500-500). The gel was stained with ethidium 
bromide (Sigma, #E1510), with 1 µl of ethidium bromide 
added to each 300 ml of melted agarose. Then, 6 µl of the 
100 bp DNA ladder (NEB, #N3231S) and 8 µl of each PCR 
sample was loaded into each well and electrophoresis was 
performed at 70 V. Separated samples were visualised by 
means of ultraviolet light through safety glass/visors as well 
as being photographed.
Amplicon sequencing
The desired PCR products were carefully cut out of the 
gel and the DNA fragments extracted and purified using a 
QIAquick Gel Extraction Kit (Qiagen, #28704) per manu-
facturer’s protocols. A small amount of the purified product 
was run on a 2% agarose gel to ensure the correct size was 
maintained. The remaining purified product, with DNA con-
centration of 20–30 ng/µl ) was sent to the GATC service, 
(Germany) for sequencing.
Results
PCR amplicons of various sizes were detected with many 
intron-spanning primer combinations.
Exon 12 (penultimate 3’ exon) splicing
Amplicons of 2 sizes, differing by ~ 150 bp, were detected 
in microglial cells with primers from exon 10 to exon 13 
(Fig. 2a). The larger amplicon, confirmed by sequencing to 
contain exon 12, was of notable higher intensity than the 
amplicon confirmed by sequencing to lack exon 12. Consist-
ent with this, strong amplification was obtained when prim-
ers were used that specifically amplified exon 12-containing 
transcripts (Fig. 2b-c).
Neurones and astrocytes also generated strong amplifica-
tion with primers placed within exon 12 (Fig. 3a,b). How-
ever, only transcripts containing exon 12 could be clearly 
identified - primers targetting exons 10 and 13 yielded a 
predominant band of 550 bp, whereas isoforms lacking exon 
12 would yield a 400 bp band.
VRK2 has been linked to immune responses (Lee 2019, 
Blanco et al. (2006). We therefore investigated the effect of 
immune stimulation, using the bacterial mimetic lipopoly-
saccharide (LPS), on Vrk2 transcript expression. While LPS 
produced a clear inflammatory response in the microglial 
cells (assessed by iNOS induction, Supplementary Fig. 1), 
no alteration in the expression of a variety of amplicons was 
detected (Supplementary Fig. 2).
5’ exon splicing
Only a single amplicon of around 350 bp was observed when 
primers targetting exons 1–2 were employed in the micro-
glial cells (Supplementary Fig. 2). However, when mouse 
brain tissue was studied, an extra amplicon was observed, 
which was larger by ~ 200 bp (Fig. 3c), suggesting the pres-
ence of an additional exon between exons 1 and 2. This extra 
size was also detected in longer transcripts from neurons 
and astrocytes, whatever the position of the reverse primer 
(Fig. 3d).
We tested an additional forward primer located further 
upstream from the start of exon 1, to test for the possible 
presence of an additional 5’ exon. The Ensembl database 
shows an automated prediction of an exon in this region, 
derived from a potential Vrk2 transcript that terminates in 
exon 4. Using a forward primer designed for this exon (which 
we term exon 1a), three PCR amplicons were detected with 
the same reverse primer (exon2), in brain tissue and in cul-
tured neurones and astrocytes (Fig. 4a). Microglial cells, 
and also cerebellar tissue, only showed the presence of the 
smallest exon 1a-containing amplicon, suggesting that they 
do not express splice variants containing exons 1 and 1b as 
well as 1a.
Sequencing of the amplicons revealed that the shortest 
(185 bp) amplicon has exon 1a spliced directly to exon 2, 
the middle amplicon contains exon 1a, exon 1 and exon 2, 
and the longest (723 bp) amplicon contains exon 1a, exon 1, 
and an additional exon (which we term exon 1b) derived by 
the lack of a splicing event at the end of exon 1 (Fig. 4d and 
Supplementary Fig. 3).
If the automated prediction exon start site is presumed 
correct, then exon 1a is 80 bp in length. Our data show that 
exon 1b is 205 bp in length. Neither exon is predicted to alter 
the open reading frame (Supplementary Fig. 3).
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Fig. 2  Isoform detection in microglia. cDNA was prepared from 
microglial cells, and amplified with primers spanning exons 10 to 13 
(a), 8 to 12 (b) and 12 to 13 or 10 to 12 (c). Alignment of sequenced 
amplicons from A (arrows) against the Ensembl genome browser is 
also shown (d), with location of F10 and R13 primers (arrowheads). 
Exon 12 is 147 bp in length
Fig. 3  Isoform detection in neurones, astrocytes and microglia. a,b 
cDNA prepared from primary neuronal cultures (a), or primary astro-
cyte cultures (b), was amplified with primers targetting exons 10–13. 
In all cases, amplicons are obtained when the primer sequence lies 
within exon 12. Note that the predicted amplicon for isoforms lack-
ing exon 12 (400 bp with F10 R13) is not detected in neurones or 
astrocytes. c, d Transcripts amplified containing exon 1. c expression 
of 5’ exons in adult mouse prefrontal cortex (PFC) and hippocam-
pus (HPC): amplicons were generating using F1 and R2 primers. d 
amplicons generated using F1 and R9 primers in cDNA from cultured 
neurones, or using F1 and R6/7 primers in cDNA from cultured astro-
cytes. In each case, 2 bands differing in size by around 200 bp are 
obtained
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Exposure of microglial cells to an immune stimulus (100 
ng/ml LPS, 24 h) resulted in an increase in the expression of 
the exon 1a-containing transcripts (Fig. 4b, c).
Amplicons were identified that stretched from exon 
1a through to exon 13. A truncated transcript of around 
750 bp was also detected in microglial cells, which was 
revealed by sequencing to lack exons 4–10 (Fig. 5a-c). 
Fig. 4  Transcripts amplified containing exon 1a. Expression of 5’ 
exons including exon 1a in a brain tissue (embryonic E17 whole 
brain, CBM, PFC or HPC) different CNS cell types (microglia, neu-
rones or astrocytes), and b microglial cells exposed to either vehicle 
or LPS (100 ng/ml) for 18 h. c Graph shows amplicon band inten-
sity for the larger and smaller bands in C (individual data points with 
mean +/- s.e.m.). # p < 0.05 vs. corresponding vehicle group; Mann 
Whitney test ** p = 0.015 vs. corresponding vehicle group (one sided 
t-test). d Location of F1a1 and R2 primers (arrowheads), along with 
alignment of sequenced amplicons from brain (185 bp, 520 and 720 
bp) (arrows) against the Ensembl genome browser. The amplicons 
represent exons 1a, 1a + 1, and 1a + 1 + 1b, respectively, plus exon 2
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A similar short amplicon of around 800 bp was obtained 
using primers targetting exons 1 and 13 in mouse prefron-
tal cortex tissue (Fig. 5a).
Discussion
Most previous studies of VRK2 expression have focussed 
on proliferating cells, despite the emerging importance 
of VRK2 for the aetiology of psychiatric disease. To test 
for cell-type-specific expression in the CNS, we analysed 
Fig. 5  Identification of full length transcripts (exon 1a-13), and also 
an atypical isoform lacking exons 4–10. a Left panel: two major 
sizes of amplicons were obtained from microglial cells using primers 
targetting exon 1a and exon 13. Right panel: a single amplicon was 
obtained from adult mouse prefrontal cortex tissue using primers tar-
getting exon 1 and exon 13. b,c Alignment of sequenced 1500 bp and 
800 bp amplicons (arrows) from microglial cells against the Ensembl 
genome browser is shown for the 5’ end of the gene b and for the full 
gene c (Note that both transcripts lack exon 1). Location of F1a1 and 
R13 primers is also shown (arrowheads)
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RNA extracts from cultured neurons and astrocytes, and 
from a cultured mouse microglial cell line. Unexpectedly, 
Vrk2 seems to be expressed in all three cell types. Lee 
et al. [12] reported, using RT-PCR targetting exon 13, that 
Vrk2 expression in the mouse CNS is confined to micro-
glia. The reasons for the discrepancy with our study are 
not clear. While we have not definitively characterised the 
3’ end of all the splice variants reported here, amplicons 
containing exon 13 did not show preferential expression 
in microglial cells.
We confirm the existence, in the mouse, of homologues 
of the human VRK2A and VRK2B isoforms, lacking and 
containing the penultimate 3’ exon. We also report addi-
tional complexity in the alternative splicing of other exons 
of the mouse Vrk2 gene. Interestingly, the expression pat-
tern for the various isoforms is highly variable among the 
different cell type. For example, transcripts containing the 
newly-identified exon 1a do not also contain exon 1 in 
microglia, whereas longer exon 1a-containing transcripts 
are also found in neurones and astrocytes. Interestingly, 
of the exon 1a-containing isoforms, the shortest (exon 1 
and 1b-lacking) transcripts appear to predominate in all 
cell types.
The heterogeneity of 5’ utr variants is remarkable. We 
confirmed that full length transcripts incorporating exon 
1a are expressed (Fig. 5). As far as we can ascertain, none 
of the novel variants extends the ORF, hence leaving the 
N-terminal protein sequence unaffected. The functional 
significance, of a process that is clearly regulated by cell 
type and environment, remains to be determined. Note that 
the Ensembl database records human VRK2 isoforms with 
between 3 and 6 additional 5’ exons upstream of the exon 
conventionally designated “exon 1” by Palo and cowork-
ers, by Niskrat and Taco, and by ourselves. These additional 
exons are also not predicted to change the ORF. One pos-
sibility is that the increasing 5’utr lengths allow increased 
thermodynamic stability of tertiary structure, thus impeding 
translation. Indeed RNAfold [25] predicts that the 1a-, 1a-1- 
and 1a-1-1b- 5’utrs have tertiary structures with negative 
free energies of 52, 240 and 357 kcal/mol respectively.
Cell samples were also analysed for the presence of an 
alternative isoform that lacks exon 12. We found this isoform 
was expressed in microglia, but was not clearly detected in 
astrocytes or neurons (Fig. 3). The isoform lacking exon 
12 (corresponding to VRK2A in human) is the cytoplas-
mic form, while the longer mRNA VRK2B form is nuclear 
[14, 15]. It therefore appears that the cytoplasmic function 
is more relevant for microglial cells in the CNS. It is inter-
esting to note that VRK2A is more abundant than VRK2B 
in a variety of (highly proliferative) tumour cell lines [13], 
whereas our data suggest that VRK2B is more abundant in 
slowly-proliferating cells (microglia and astrocytes) and non-
proliferating cells (neurons). We speculate that prominent 
VRK2A expression may relate to the suggested role of 
VRK2 in cell proliferation, and that higher relative VRK2B 
expression may be a feature of non-proliferating cells. We 
note that the brain tissue used here was derived from male 
mice, and it should be remembered that sex-differences can 
play a role in gene expression in brain [26], and hence that 
female tissue may show differences.
We also detected the presence of a truncated transcript, 
which sequencing revealed to be missing 7 central exons 
(exons 4–10). This truncated form produces a predicted pro-
tein of only 59 amino acids, where the C-terminal 17 amino 
acids (QENFESRWSTFRATGIFH) are not present in the 
longer forms of the protein. The functional significance of 
this new variant is not clear. It is expressed in microglial 
cells, but will not have a functional catalytic site, or the JIP-1 
binding site [15]. In terms of CNS disease risk, the epi-
lepsy risk mutation identified is within exon 2 [8], while the 
bipolar disorder mutation is in exon 4 [7]. This transcript is 
therefore unlikely to contribute to bipolar disorder risk, but 
may play a role in epilepsy. The precise exon composition 
of variants expressed in neurones and astrocytes that contain 
the catalytic site remains to be determined, although they 
clearly exist (Fig. 3d), and will presumably contain exon 12. 
However, the data emphasise the differences between Vrk2 
spicing in neurones/astrocytes and microglial cells.
LPS treatment induces alternative splicing
Vrk2 is known for its role in modulating inflammatory 
responses, thus one aim of this study was to investigate the 
correlation between inflammatory status and the distribution 
of splicing events in LPS stimulated microglial cells. LPS is 
a well-characterised bacterial mimetic that elicits inflamma-
tory response in the brain. No obvious differences in expres-
sion were detected for canonical transcripts (containing exon 
1) or for the main transcripts either containing or lacking 
exon 12 (Supplementary Fig. 2). Intriguingly, transcripts 
containing exon 1a showed clearly stronger expression in 
the LPS-treated cells (Fig. 4). This indicates that Vrk2 splic-
ing pattern is altered by immune stimuli, and suggests some 
particular immune-response function for exon 1a.
Conclusions
Overall, our data reveal the existence of novel alterna-
tively-spliced isoforms of VRK2, and indicate that splic-
ing is regulated according to cell type, brain region, and 
environmental conditions. Further investigations will be 
required to understand the functional significance of these 
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complex patterns of splicing, and whether similar com-
plexity exists in the human gene.
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